Alkermes said two late-stage studies of its treatment for major depressive disorder didn't meet their primary endpoints, a significant setback for the company, erasing nearly a third of its market value.
from WSJ.com: US Business http://ift.tt/1PGXANo
via IFTTT
No comments:
Post a Comment